Theranos, the blood-testing startup with a $9 billion valuation, has had a turbulent year.
On Wednesday, the company made major changes to the company, including the announcement that its president and chief operating officer Sunny Balwani, who served as CEO and founder Elizabeth Holmes’ second-in-command, is retiring.
Here’s a review of the events that led up to this point over the last year.
Dragan Radovanovic/Business Insider
CHECK OUT:Theranos is at a critical turning point — what it does next could determine the company’s future
RELATED:Theranos announced a major management shakeup
NOW WATCH: Doctors now say this type of cancer isn’t actually cancer — and the new classification is changing thousands of lives
Loading video…
